{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:8168"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:8168","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The epigenetic and transcriptional consequences of aberrant FoxC1 expression in acute myeloid leukaemia","abstract":"FOXC1 encodes a mesenchymal transcription factor that is not normally expressed in haematopoietic cells. However, recent studies from this and another laboratory demonstrated that FOXC1 is inappropriately de-repressed in Acute Myeloid Leukaemia (AML). Through epigenomic profiling of primary AML samples, we showed that FOXC1 was specifically upregulated in the aggressive FLT3-ITD subtype of AMLs, in parallel with the activation of FOX:E-box composite cis-regulatory elements. Furthermore, complementary studies from the Somervaille laboratory demonstrated that FoxC1 expression in AML was leukaemogenic by establishment of a monocyte differentiation block and enhancement of clonogenic potential. Collectively, these data indicated that FoxC1 plays a critical role in leukaemogenesis, but the target genes and mechanisms by which this occurred were not known. To address this, we performed an integrative genome-wide analysis of FoxC1 binding, chromatin accessibility and gene expression in primary AML samples, in vivo models and cell lines. These studies revealed that FoxC1 acts to block normal myeloid differentiation by contributing to the widespread repression of differentiation-specific target genes. Critically, we identify Meis2, a proto-oncogene which collaborates with Hoxa9, as a putative direct target of FoxC1, providing compelling indications of a potential FoxC1-dependent oncogenic mechanism.","abstract_html":"FOXC1 encodes a mesenchymal transcription factor that is not normally expressed in haematopoietic cells. However, recent studies from this and another laboratory demonstrated that FOXC1 is inappropriately de-repressed in Acute Myeloid Leukaemia (AML). Through epigenomic profiling of primary AML samples, we showed that FOXC1 was specifically upregulated in the aggressive FLT3-ITD subtype of AMLs, in parallel with the activation of FOX:E-box composite cis-regulatory elements. Furthermore, complementary studies from the Somervaille laboratory demonstrated that FoxC1 expression in AML was leukaemogenic by establishment of a monocyte differentiation block and enhancement of clonogenic potential. Collectively, these data indicated that FoxC1 plays a critical role in leukaemogenesis, but the target genes and mechanisms by which this occurred were not known. To address this, we performed an integrative genome-wide analysis of FoxC1 binding, chromatin accessibility and gene expression in primary AML samples, in vivo models and cell lines. These studies revealed that FoxC1 acts to block normal myeloid differentiation by contributing to the widespread repression of differentiation-specific target genes. Critically, we identify Meis2, a proto-oncogene which collaborates with Hoxa9, as a putative direct target of FoxC1, providing compelling indications of a potential FoxC1-dependent oncogenic mechanism.","abstract_has_math":false,"creators":["Gilding, Liam Niall"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-07","date_published":"2018-07","updated_at":"2026-11-19T09:30:03Z","subjects":["QH426 Genetics","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/8168/2/Gilding18PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A8168","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["bloodwise"]},{"key":"dc:creator","label":"Author","values":["Gilding, Liam Niall"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-07"]},{"key":"dc:date.issued","label":"Date","values":["2018-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/8168/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QH426 Genetics","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/8168/2/Gilding18PhD.pdf","http://etheses.bham.ac.uk//id/eprint/8168/1/Decl_IS_Gilding18PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["FOXC1 encodes a mesenchymal transcription factor that is not normally expressed in haematopoietic cells. However, recent studies from this and another laboratory demonstrated that FOXC1 is inappropriately de-repressed in Acute Myeloid Leukaemia (AML). Through epigenomic profiling of primary AML samples, we showed that FOXC1 was specifically upregulated in the aggressive FLT3-ITD subtype of AMLs, in parallel with the activation of FOX:E-box composite cis-regulatory elements. Furthermore, complementary studies from the Somervaille laboratory demonstrated that FoxC1 expression in AML was leukaemogenic by establishment of a monocyte differentiation block and enhancement of clonogenic potential. Collectively, these data indicated that FoxC1 plays a critical role in leukaemogenesis, but the target genes and mechanisms by which this occurred were not known. To address this, we performed an integrative genome-wide analysis of FoxC1 binding, chromatin accessibility and gene expression in primary AML samples, in vivo models and cell lines. These studies revealed that FoxC1 acts to block normal myeloid differentiation by contributing to the widespread repression of differentiation-specific target genes. Critically, we identify Meis2, a proto-oncogene which collaborates with Hoxa9, as a putative direct target of FoxC1, providing compelling indications of a potential FoxC1-dependent oncogenic mechanism."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["The epigenetic and transcriptional consequences of aberrant FoxC1 expression in acute myeloid leukaemia"]}]}],"canonical_facts":{"dc:contributor.sponsor":["bloodwise"],"dc:creator":["Gilding, Liam Niall"],"dc:date":["2018-07"],"dc:date.issued":["2018-07"],"dc:description.abstract":["FOXC1 encodes a mesenchymal transcription factor that is not normally expressed in haematopoietic cells. However, recent studies from this and another laboratory demonstrated that FOXC1 is inappropriately de-repressed in Acute Myeloid Leukaemia (AML). Through epigenomic profiling of primary AML samples, we showed that FOXC1 was specifically upregulated in the aggressive FLT3-ITD subtype of AMLs, in parallel with the activation of FOX:E-box composite cis-regulatory elements. Furthermore, complementary studies from the Somervaille laboratory demonstrated that FoxC1 expression in AML was leukaemogenic by establishment of a monocyte differentiation block and enhancement of clonogenic potential. Collectively, these data indicated that FoxC1 plays a critical role in leukaemogenesis, but the target genes and mechanisms by which this occurred were not known. To address this, we performed an integrative genome-wide analysis of FoxC1 binding, chromatin accessibility and gene expression in primary AML samples, in vivo models and cell lines. These studies revealed that FoxC1 acts to block normal myeloid differentiation by contributing to the widespread repression of differentiation-specific target genes. Critically, we identify Meis2, a proto-oncogene which collaborates with Hoxa9, as a putative direct target of FoxC1, providing compelling indications of a potential FoxC1-dependent oncogenic mechanism."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/8168/2/Gilding18PhD.pdf","http://etheses.bham.ac.uk//id/eprint/8168/1/Decl_IS_Gilding18PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer and Genomic Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/8168/"],"dc:subject":["QH426 Genetics","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["The epigenetic and transcriptional consequences of aberrant FoxC1 expression in acute myeloid leukaemia"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:30:03Z"}